Ali Khademhosseini

Ali Khademhosseini is the CEO and Director of Terasaki Institute for Biomedical Innovation, a research organization focused on enabling translational science and academic entrepreneurship. Ali is also the Founder and CEO of Omeat. Previously, Ali was a Co-Founder and Board member of Obsidio, Inc., a company that developed FDA cleared embolic material and was later sold to Boston Scientific. With a background in bioengineering and biomedical engineering, Ali has held various prestigious academic positions at institutions such as Harvard University, University of California, Los Angeles, and Massachusetts Institute of Technology.